Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963262 | 0.85 | CYP2D6 (0.44) | SIGMAR1OPRD1HSD11B1 | |
| SCHEMBL9966022 | 0.73 | KMT2A (0.40) | KMT2ARORC | |
| SCHEMBL10339511 | 0.73 | ACHE (0.48) | KMT2ASIGMAR1TSHR | |
| SCHEMBL15099404 | 0.72 | TSHR (0.44) | KMT2ASIGMAR1DRD2TSHRSLC6A2 | |
| SCHEMBL15099393 | 0.71 | CHRM2 (0.41) | KMT2ASIGMAR1DRD2TSHRSLC6A2 | |
| SCHEMBL11275319 | 0.68 | CHRM1 (0.43) | KMT2ASIGMAR1DRD2TSHRCHRM1 | |
| SCHEMBL11618119 | 0.67 | SLC6A2 (0.53) | KMT2ATSHRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9965895 | 0.66 | KCNH2 (0.58) | KMT2ASIGMAR1OPRD1DRD2HSD11B1 | |
| SCHEMBL742078 | 0.66 | SIGMAR1 (0.65) | SIGMAR1 | |
| SCHEMBL4343470 | 0.65 | KMT2A (0.62) | KMT2ASIGMAR1OPRD1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KMT2A 4265/4885SIGMAR1 152/4885OPRD1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.